Stock Report

Download full stock data and analysis for free Last Updated: 20-Oct-2026

Stock Rating

Is this stock worth it? Our ratings reveal the truth.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Bacil Pharma Key Ratios

Stock Card factsheet watchlist-stock-modal share-fund-plan-icon

BSE: 524516

₹20.34

up-down-arrow ₹-1.07 (-5.00%)

As on 19-Oct-2026IST

Market cap

info icon

₹29 Cr

Revenue (TTM)

info icon

₹0 Cr

P/E Ratio

info icon

46

P/B Ratio

info icon

1.1

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue -- -- -- -- --
EBIT -156.52 -63.89 60.78 3.47 9.15
Net Profit 43.75 -164.29 -38.05 95.52 31.53
EPS 44.35 -164.00 -32.45 62.72 23.01
Book Value -- -- 1,801.64 165.20 70.99
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMMar-25Mar-24
EBIT-Margin info ----------
Net Margin info ----177.37----
Return on equity info -9.21-126.982.543.19-11.38
Return on Capital info -3.41-59.71--3.03-4.80
Return on Assets info -3.85-33.542.453.01-5.18
Debt to Equity (x) info ----0.000.010.08

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Bacil Pharma
--
3.03
-4.80
-8.45
-273.27
Peer Median
--
14.72
18.85
11.60
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

2.54

Lower than Peers by 8.32

Profit after tax / Average Net worth * 100

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Bacil Pharma
2.54
3.19
-11.38
-19.42
-575.48
Peer Median
10.86
11.67
14.92
11.46
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

2.45

Lower than Peers by 4.31

Profit after tax / Average Total assets * 100

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Bacil Pharma
2.45
3.01
-5.18
-9.37
-150.07
Peer Median
6.76
7.86
9.06
6.44
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

177.37

Higher than Peers by 168.49

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Bacil Pharma
177.37
61.11
-45.29
-88.92
-6,704.78
Peer Median
8.89
9.33
8.49
10.02
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

EBIT Growth

60.78

Higher than Peers by 43.95

Year on year growth in operating profit (EBIT)

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Bacil Pharma
60.78
-34.36
12.14
94.51
-1,167.86
Peer Median
16.82
24.15
28.00
-3.12
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

-38.05

Lower than Peers by 54.34

Year on year growth in profit after tax

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Bacil Pharma
-38.05
783.93
42.00
97.36
-1,513.41
Peer Median
16.29
30.29
36.51
-0.85
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

-32.45

Lower than Peers by 41.96

Year on year growth in earnings per share

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Bacil Pharma
-32.45
402.29
42.02
97.36
-1,513.29
Peer Median
9.52
24.50
--
-6.82
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

--

--

Year on year growth in book value per share

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Bacil Pharma
--
4,204.55
24.59
-21.28
-22.14
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

--

--

Total debt / Net worth

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Bacil Pharma
--
0.01
0.08
0.02
0.03
Peer Median
0.04
0.23
0.20
0.15
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

--

--

(Short term borrowings / Net worth)

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Bacil Pharma
--
0.01
0.08
0.02
0.03
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

20.71

Higher than Peers by 18.96

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Bacil Pharma
20.71
17.21
0.46
8.20
6.69
Peer Median
1.76
1.79
1.96
2.08
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

20.71

Higher than Peers by 19.53

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Bacil Pharma
20.71
17.21
0.46
8.20
6.69
Peer Median
1.19
1.47
1.44
1.58
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

--

--

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Bacil Pharma
--
--
-83.43
-66.93
-4,517.88
Peer Median
8.12
9.42
8.58
15.41
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Asset Turnover

--

--

Sales / Average Total Assets

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Bacil Pharma
--
--
--
--
--
Peer Median
0.67
0.75
0.77
0.65
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Bacil Pharma
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Valuation

View Detailed Peer Comparison

Price / Earnings

45.97

Higher than Peers by 5.75

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Bacil Pharma
45.97
140.14
--
--
--
Peer Median
40.23
39.70
33.48
37.74
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

1.14

Lower than Peers by 3.30

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Bacil Pharma
1.14
2.28
14.96
6.98
5.75
Peer Median
4.43
3.72
4.21
3.22
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Bacil Pharma
--
--
--
--
--
Peer Median
0.20
0.16
0.21
0.57
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

164.15

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Bacil Pharma
164.15
132.15
-154.07
-32.95
-0.82
Peer Median
--
30.23
29.90
28.81
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

29

Lower than Peers by 7,532

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Bacil Pharma
29
--
--
--
--
Peer Median
7,561
4,851
2,099
15,272
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...